United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales. See the ...

The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an ...

MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...

Its key medications—Remodulin, Tyvaso, and Orenitram—are sold to patients, hospitals, and specialty pharmacies. United Therapeutics Corporation (NASDAQ:UTHR) ended 2024 with record revenue and ...

At the moment, the only FDA-approved treatment for PH-ILD is United Therapeutics' Tyvaso inhaled prostacyclin analogue (treprostinil), which is delivered either using a nebuliser or as a DPI four ...

Earlier this month, the company announced that it had completed the full enrollment in the phase III TETON 1 study, which is evaluating the use of Tyvaso (treprostinil) inhalation solution ...

United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.